Vaxart Company profile
Vaxart Inc. is a clinical-stage biotechnology company headquartered in San Francisco, California. It works on the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. It also has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program.
Vaxart is traded on the Nasdaq under the ticker VXRT. In its finance for Q4 2021, the company reported revenue totalling $0.89m, a 77.9% decrease from the $4.04m result in 2020.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)